219 related articles for article (PubMed ID: 36407083)
21. Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Pelusi S; Baselli G; Pietrelli A; Dongiovanni P; Donati B; McCain MV; Meroni M; Fracanzani AL; Romagnoli R; Petta S; Grieco A; Miele L; Soardo G; Bugianesi E; Fargion S; Aghemo A; D'Ambrosio R; Xing C; Romeo S; De Francesco R; Reeves HL; Valenti LVC
Sci Rep; 2019 Mar; 9(1):3682. PubMed ID: 30842500
[TBL] [Abstract][Full Text] [Related]
22. miR-363-5p as potential prognostic marker for hepatocellular carcinoma indicated by weighted co-expression network analysis of miRNAs and mRNA.
Zhang J; Fan J; Zhou C; Qi Y
BMC Gastroenterol; 2017 Jun; 17(1):81. PubMed ID: 28637446
[TBL] [Abstract][Full Text] [Related]
23. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
24. NAFLD Related-HCC: The Relationship with Metabolic Disorders.
Zhang X
Adv Exp Med Biol; 2018; 1061():55-62. PubMed ID: 29956206
[TBL] [Abstract][Full Text] [Related]
25. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
[TBL] [Abstract][Full Text] [Related]
26. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
Di Maira G; Foglia B; Napione L; Turato C; Maggiora M; Sutti S; Novo E; Alvaro M; Autelli R; Colombatto S; Bussolino F; Carucci P; Gaia S; Rosso C; Biasiolo A; Pontisso P; Bugianesi E; Albano E; Marra F; Parola M; Cannito S
J Pathol; 2022 May; 257(1):82-95. PubMed ID: 35064579
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma.
Jeong S; Shin WY; Oh YH
Front Endocrinol (Lausanne); 2023; 14():1150360. PubMed ID: 37020584
[TBL] [Abstract][Full Text] [Related]
28. mTOR direct crosstalk with STAT5 promotes de novo lipid synthesis and induces hepatocellular carcinoma.
Li T; Weng J; Zhang Y; Liang K; Fu G; Li Y; Bai X; Gao Y
Cell Death Dis; 2019 Aug; 10(8):619. PubMed ID: 31409773
[TBL] [Abstract][Full Text] [Related]
29. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
30. Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2/AKT pathway.
Chi Y; Gong Z; Xin H; Wang Z; Liu Z
J Transl Med; 2020 Mar; 18(1):126. PubMed ID: 32169080
[TBL] [Abstract][Full Text] [Related]
31. Identification of key modules and driving genes in nonalcoholic fatty liver disease by weighted gene co-expression network analysis.
Song Z; Wang Y; Lin P; Yang K; Jiang X; Dong J; Xie S; Rao R; Cui L; Liu F; Huang X
BMC Genomics; 2023 Jul; 24(1):414. PubMed ID: 37488473
[TBL] [Abstract][Full Text] [Related]
32. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
33. NAFLD-related HCC.
Banini BA; Sanyal AJ
Adv Cancer Res; 2021; 149():143-169. PubMed ID: 33579423
[TBL] [Abstract][Full Text] [Related]
34. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Zhang C; Wang P; Li Y; Huang C; Ni W; Chen Y; Shi J; Chen G; Hu X; Ye M; Duan S; Wang K
Anat Rec (Hoboken); 2019 Feb; 302(2):193-200. PubMed ID: 30312023
[TBL] [Abstract][Full Text] [Related]
35. Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma.
Kurokawa S; Yoneda M; Ogawa Y; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A; Hotta K
BMC Gastroenterol; 2022 Jun; 22(1):278. PubMed ID: 35655171
[TBL] [Abstract][Full Text] [Related]
36. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K
J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889
[TBL] [Abstract][Full Text] [Related]
37. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans.
Chen K; Ma J; Jia X; Ai W; Ma Z; Pan Q
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):117-125. PubMed ID: 30528647
[TBL] [Abstract][Full Text] [Related]
38. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
39. [Quantitative detection and clinical value of CD44 in patients with nonalcoholic fatty liver disease].
Fang M; Yao M; Yang JL; Wang L; Sun JY; Wu MN; Yao DF; Tai BJ
Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):994-1000. PubMed ID: 31941262
[No Abstract] [Full Text] [Related]
40. Immune-metabolic interactions in homeostasis and the progression to NASH.
Hoogerland JA; Staels B; Dombrowicz D
Trends Endocrinol Metab; 2022 Oct; 33(10):690-709. PubMed ID: 35961913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
